Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
May 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
May 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
May 05, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
April 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
April 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
April 01, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
March 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
March 29, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
March 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
March 24, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
March 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
February 18, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
February 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 10, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
February 09, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
January 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
January 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides 2021 Year End Summary
December 22, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
December 21, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
December 15, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
December 08, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
December 01, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
November 30, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
November 29, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
November 23, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.